Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2015

Summary of Revenue Recognized under Agreement

		Years Ended December 31,
Agreement	Deliverable	2015		2014		2013
Japan	License	$	1,024	$	518	$	566
	Milestones		—		—		12,500
	Total license and milestone revenue	$	1,024	$	518	$	13,066
	Collaboration services revenue*	$	198	$	356	$	433

When and if available compounds, manufacturing — clinical supplies and committee services have each been identified as separate units of accounting with standalone value and amounts allocable to these elements have been recognized and classified within the Collaboration services revenue line item within the consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Japan Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2015		Deferred Revenue at December 31, 2015		Total Consideration Through December 31, 2015
License	$	42,245	$	—	$	42,245
When and if available compounds		14		28		42
Manufacturing--clinical supplies		1,966		—		1,966
Committee services		16		—		16
Total license and collaboration services revenue	$	44,241	$	28	$	44,269

Europe [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the Europe Agreement were as follows (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2015		2014		2013
Europe	License	$	17,677	$	13,935	$	9,260
	Milestones		—		—		—
	Total license and milestone revenue	$	17,677	$	13,935	$	9,260
	Collaboration services revenue*	$	2,697	$	3,179	$	2,902

When and if available compounds, manufacturing — clinical supplies, development services — in progress at the time of signing of the agreement, and committee services have each been identified as a separate unit of accounting with standalone value and amounts allocable to these units have been recognized in revenue as services are performed and classified within the Collaboration services revenue line item within the consolidated statements of operations.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the Europe Agreement, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2015		Deferred Revenue at December 31, 2015		Total Consideration Through December 31, 2015
License	$	401,316	$	—	$	401,316
When and if available compounds		332		432		764
Manufacturing--clinical supplies		9,612		—		9,612
Development services--in progress		32,154		—		32,154
Committee services		278		—		278
Total license and collaboration services revenue	$	443,692	$	432	$	444,124

U.S./RoW [Member]

Summary of Revenue Recognized under Agreement

Amounts recognized as revenue under the U.S./RoW and China Agreements were as follows (in thousands):

		Years Ended December 31,
Agreement	Deliverable	2015		2014		2013
U.S. / RoW and China	License	$	114,392	$	102,738	$	72,635
	Milestones		15,000		—		—
	Total license and milestone revenue	$	129,392	$	102,738	$	72,635
	Collaboration services revenue*	$	29,731	$	16,820	$	3,843
	China single unit of accounting**	$	—	$	—	$	—

Co-development, information sharing, and committee services have been combined into a single unit of accounting because the requirements to share information and serve on committees are useful only in combination with the development services, and because all three items are delivered over the same period while manufacturing — clinical supplies has been identified as a separate unit of accounting with standalone value and amounts allocable to this unit of accounting have been recognized and classified within the Collaboration services revenue line item within the consolidated statements of operations.

All revenues attributable to the China unit of accounting are deferred until all deliverables are met. The China license and collaboration services elements have been combined into a single unit of accounting and consideration allocable to this unit is being deferred due to FibroGen’s retention of manufacturing rights and lack of standalone value.

Total Arrangement Consideration Allocated to Deliverables along with Associated Deferred Revenue

The total arrangement consideration has been allocated to each of the following deliverables under the U.S./RoW and China Agreements, along with any associated deferred revenue as follows (in thousands):

	Cumulative Revenue Through December 31, 2015		Deferred Revenue at December 31, 2015		Total Consideration Through December 31, 2015
License	$	289,766	$	—	$	289,766
Co-development, information sharing & committee services		50,162		37,936		88,098
Manufacturing--clinical supplies		232		70		302
China-single unit of accounting		—		59,394		59,394
Total license and collaboration services revenue	$	340,160	$	97,400	$	437,560